← All resources

GLP-1 Collective · Free tool · GLP-1 medications

Every GLP-1, explained simply.

Compare every GLP-1 medication, from the first one approved to the newest options still in development. See what each medication is approved for, how it is taken, how it works, and what clinical trials have found so far.

Highlight up to 4 to compare them in a table.

This is education, not a recommendation

Which of these fits you — if any — depends on your health history, your insurance, and your prescriber's judgment. Trial percentages are averages from different trials with different lengths and populations, so treat them as a rough map, not a ranking. Bring this page to your appointment if it helps the conversation; do not use it in place of one.

Sources

  1. Wegovy (semaglutide) Prescribing Information. Novo Nordisk. Current label at DailyMed and the FDA label for Wegovy tablets. Indications including cardiovascular risk reduction and MASH, and the oral tablet approval.
  2. Zepbound (tirzepatide) Prescribing Information. Eli Lilly. FDA label. The weight-management and obstructive sleep apnea indications.
  3. Ozempic (semaglutide) Prescribing Information. Novo Nordisk. Current label. The type 2 diabetes, cardiovascular, and chronic kidney disease indications.
  4. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183. The ~15% figure for semaglutide 2.4 mg.
  5. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. The up-to-21% figure for tirzepatide 15 mg.
  6. Pi-Sunyer X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). New England Journal of Medicine. 2015;373(1):11–22. doi:10.1056/NEJMoa1411892. The ~8% figure for liraglutide 3.0 mg.
  7. Eli Lilly. Orforglipron ATTAIN-1 phase 3 results, published in the New England Journal of Medicine. Company announcement. The ~12% (27 lb) average at the highest dose over 72 weeks.
  8. American Diabetes Association / Novo Nordisk. CagriSema REDEFINE-1 phase 3 results. ADA announcement. The ~20% average (about 23% with full adherence) at 68 weeks.
  9. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972. The up-to-24% figure at 48 weeks.
  10. ASHP Drug Shortages Database: Exenatide. ashp.org. Documentation of the Byetta and Bydureon discontinuations.